Insights on Integrating New Treatments for HER2+ EBC - priME Oncology
Webcast
Webcast

Insights on Integrating New Treatments for HER2+ EBC

Time for a Risk-Adapted Approach

View Activity

Not a member of My prIME? Join now for instant access.

The information in this activity is intended for healthcare professionals based outside of the United States. You will be asked to provide your credentials before participating in the activity. This activity may contain information on products outside the approved indications where you practice.

Enhance your understanding of optimal treatment approaches for HER2+ early breast cancer with this webcast of our symposium held in Madrid. A variety of therapeutic strategies are covered, including short duration regimens, extended adjuvant therapy, dual HER2 blockade, and patient selection for these strategies. Optimizing the risk-benefit profile of different regimens is also addressed, with information on prevention and management of adverse events. Finally, emerging agents and potential future opportunities provided by new HER2-targeted strategies that address areas of continuing unmet clinical need are covered.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 16, 2017

Expiration Date

Oct 16, 2018

The case for dual blockade
Sibylle Loibl, MD, PhD 

The case for extended adjuvant treatment
Michael Untch, MD, PhD

The case for reduced treatment
Thomas Bachelot, MD, PhD

Optimizing the risks and benefits of treatment
Wolfgang Janni, MD, PhD

Borrowing from Maria to treat Sophia: A risk-adapted approach to treatment
Suzette Delaloge, MD, MSc

Emerging treatments for HER2+ and mutant breast cancer
Cristina Saura, MD

Panel Discussion
All Faculty

prIME Points™
Hope S. Rugo, MD, FACP

Chair

  • Hope S. Rugo, MD, FASCOUniversity of California, San Francisco
    Helen Diller Family Comprehensive Cancer Center
    San Francisco, California, United States

Faculty

  • Thomas Bachelot, MD, PhDCentre Léon Bérard
    Lyon, France
  • Suzette Delaloge, MD, MScGustave Roussy
    Villejuif, France
  • Wolfgang Janni, MD, PhDUniversity of Ulm
    Ulm, Germany
  • Sibylle Loibl, MD, PhDGerman Breast Group, Neu-Isenburg
    Centre for Haematology and Oncology Bethanien
    Frankfurt, Germany
  • Cristina Saura, MD, PhDVall d’Hebron University Hospital
    Barcelona, Spain
  • Michael Untch, MD, PhDHELIOS Klinikum Berlin-Buch
    Berlin, Germany

This educational activity is specifically designed for oncologists and other healthcare professionals interested in and/or involved in the treatment of breast cancer who wish to understand some of the latest developments in treatments for patients with HER2+ breast cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the results of recent clinical trials in HER2+ early breast cancer that explore the evolution of adjuvant treatment strategies
  • Select the optimum HER2-targeted strategy and duration of treatment to improve long-term disease endpoints in patients with HER2+ early breast cancer
  • Identify supportive care interventions to minimize adverse events with HER2-targeted therapy
  • Understand the limitations of health care funding for HER2+ early breast cancer and the need for a risk-adapted strategy

This educational activity is supported by a grant from Puma Biotechnology.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.